GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have become common enough that many people using them will, at some point, also be breastfeeding or considering it. The clinical guidance on combining the two remains cautious, and the evidence behind that caution is worth understanding in more detail than a label warning alone provides.
The Current Guidance
Most clinical guidance recommends avoiding GLP-1 receptor agonists while breastfeeding. FDA prescribing information for these drugs generally states that effects on a breastfed infant are unknown, reflecting a lack of the kind of controlled human data that would be needed to establish safety in this specific population. That "unknown" framing, rather than a specific documented harm, is the basis for most current caution.
What the Available Evidence Actually Shows
The limited data that does exist is somewhat reassuring on one specific point: small studies measuring drug levels in human milk have found semaglutide largely undetectable in milk samples, and tirzepatide has similarly been reported as usually undetectable or present at very low levels unlikely to be meaningfully absorbed by a nursing infant. Both drugs are large peptide molecules with poor oral bioavailability, meaning that even trace amounts present in milk would be expected to break down in an infant's digestive system rather than be absorbed intact.
What Remains Unknown
Despite that reassuring signal on direct drug transfer, several important questions remain genuinely unanswered. There's no adequate data on long-term developmental or health outcomes in infants exposed to these drugs through breast milk. There's limited information on whether GLP-1 medications affect milk supply or milk composition, given their appetite-suppressing and metabolic effects on the parent. And there's essentially no safety data specific to newborn or preterm infants, who may process even trace drug exposure differently than older infants.
Why Clinicians Tend to Recommend Caution
Part of the rationale for continued caution isn't just the biology, it's also about weighing risk against benefit. For most people using GLP-1 medications for weight management, the indication is elective rather than medically urgent, and early infancy is considered a particularly sensitive developmental window. When the underlying research is this limited, many clinicians default to the more conservative option, especially for a non-urgent indication, rather than treating an absence of evidence of harm as equivalent to evidence of safety.
Pregnancy Guidance, for Context
It's worth distinguishing breastfeeding guidance from pregnancy guidance, since the two get conflated. Semaglutide's Wegovy label recommends discontinuing the drug at least two months before a planned pregnancy, reflecting separate concerns about the drug's long elimination half-life and animal studies suggesting possible risks to fetal development. That pregnancy-specific guidance addresses a different question from breastfeeding, though both reflect the same underlying theme: an absence of solid human safety data drives conservative recommendations in each case.
What This Means for Patients
Anyone breastfeeding, planning to breastfeed, or planning a pregnancy while using a GLP-1 medication should raise it directly with their prescriber rather than making an independent decision to continue, pause, or stop the medication. This is exactly the kind of individualized risk-benefit conversation that depends on a person's specific health history, reason for taking the medication, and how replaceable or urgent the treatment is, all of which a treating physician is positioned to weigh in a way general guidance cannot.
The Bottom Line
The evidence on GLP-1 medications and breastfeeding is reassuring on the narrow question of how much drug reaches an infant through milk, but far too limited to call the combination established as safe. Current guidance reflects that gap, favoring caution over an elective indication until better data exists.